Oil stocks, GSK weakness pull FTSE 100 lower; Deliveroo jumps

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)

* Deliveroo fourth-quarter order growth jumps

* Premier Foods top midcap gainer on strong profit outlook

* Unilever abandons plan to buy GSK's healthcare arm

* FTSE 100 down 0.1%, FTSE 250 adds 0.3% (Updates to close)

By Shashank Nayar

Jan 20 (Reuters) - London's FTSE 100 slipped on Thursday on weakness in oil stocks and GlaxoSmithKline GSK.L , while food delivery platform Deliveroo jumped on order growth hitting the top of its outlook range.

The blue-chip index .FTSE ended 0.1% lower, weighed down by oil majors Royal Dutch Shell RDSa.L and BP BP.L as they tracked weaker crude oil prices.

GlaxoSmithKline fell 1.8% and was among the biggest loser on the FTSE 100 after consumer goods giant Unilever ULVR.L late on Wednesday effectively ended its pursuit of a business that the pharmaceuticals company plans to spin off later this year.

However, the blue-chip index is set to gain for the fifth consecutive week, helped by strength in commodity-linked shares and banking stocks, significantly outperforming the pan-European STOXX 600.

Food delivery company Deliveroo ROO.L rose 1.4% on strong fourth-quarter order value growth, resulting in it hitting the top of its outlook range for the year.

"The effective lockdown conditions created by Omicron undoubtedly helped (Deliveroo), but with restrictions starting to be lifted, this supportive trend is rapidly moving into the rear-view mirror," Russ Mould, investment director at AJ Bell, said.

British Prime Minister Boris Johnson on Wednesday announced the end of COVID-19 measures including mandatory face masks in England.

The domestically focussed mid-cap index .FTMC rose 0.3%

Primark owner Associated British Foods ABF.L dropped 4.2% after it said the spread of the Omicron coronavirus variant dented shopper numbers in December.

Premier Foods PFD.L was among the top midcap gainer, up 7.8%, and said it expects full-year profits above market expectations, as its trademark Mr Kipling brand delivered its best-ever Christmas sales.
Reporting by Shashank Nayar and Amal S in Bengaluru; Editing by Shounak Dasgupta and Emelia Sithole-Matarise

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.